New antibody eases hemophilia treatment


A new antibody eases treatment of severe hemophilia A.

A new antibody eases treatment of severe hemophilia A. Japanese investigators studied emicizumab, a humanized bispecific antibody that mimics the cofactor function of factor VIII, in 18 patients with severe hemophilia A (with or without factor VIII inhibitors). Delivered subcutaneously weekly for 12 weeks, emicizumab markedly decreased the bleeding rate in these patients and was not associated with serious adverse events or clinically relevant coagulation abnormalities (Shima M, et al. N Engl J Med. 2016;374(2):2044-2053). 

Next: "No strings" prenatal income support improves birth outcomes

Ms Freedman is a freelance medical editor and writer in New Jersey. She has nothing to disclose in regard to affiliations with or financial interests in any organizations that may have an interest in any part of this article.

Recent Videos
cUTI Roundtable: Discussing and diagnosing these difficult infections
Willough Jenkins, MD
Discussing health care sustainability, climate change, and WHO's One Health goal | Image credit: Provided by Shreya Doshi
Willough Jenkins, MD
Screening for and treating the metatarsus adductus foot deformity |  Image Credit: UNFO md ltd
Wendy Ripple, MD
Wendy Ripple, MD
Courtney Nelson, MD
DB-OTO improved hearing to normal in child with profound genetic deafness | Image Credit: © Marija - © Marija -
© 2024 MJH Life Sciences

All rights reserved.